Seminars in Oncology
Volume 34, Issue 6 , Pages 476-490 , December 2007

The Molecular Basis of Melanomagenesis and the Metastatic Phenotype

  • A. Neil Crowson

      Affiliations

    • Departments of Dermatology, Surgery, and Pathology, University of Oklahoma and Regional Medical Laboratory, St. John Medical Center, Tulsa, OK.
    • Corresponding Author InformationAddress correspondence to A. Neil Crowson, MD, USA, Regional Medical Laboratory, St. John Medical Center, 1923 S. Utica St, Tulsa, OK 74114-4109.
    • ,
  • Cynthia Magro

      Affiliations

    • Division of Dermatopathology, Department of Pathology and Laboratory Medicine, Weill Medical College of Cornell University, New York, NY.
    • ,
  • Arlo Miller

      Affiliations

    • Department of Dermatology, Mayo Clinic, Rochester, MN.
    • ,
  • Martin C. Mihm Jr

      Affiliations

    • Departments of Dermatology and Pathology, Harvard Medical School, Massachusetts General Hospital, Boston, MA.

References 

  1. Hecht F. The annals of cancer genetics (The description by Norris of hereditary malignant melanoma of the skin in 1820). Cancer Genet Cytogenet. 1989;42:153–156
  2. Clark WH, Reimer RR, Greene M, et al. Origin of familial melanomas from heritable melanocytic lesions (“The B-K mole syndrome”). Arch Dermatol. 1978;114:732–738
  3. Lynch HT, Frichot B, Lynch JF. Familial atypical multi-mole melanoma syndrome. J Med Genet. 1978;15:352–356
  4. Miller AJ, Mihm MC. Mechanisms of disease: Melanoma. N Engl J Med. 2006;355:51–55
  5. Cannon-Albright LA, Goldgar ME, Meyer LJ, et al. Assignment of a locus for familial melanoma, MLM, to chromosome 9p13–p22. Science. 1992;258:1148–1152
  6. Nancarrow DJ, Mann GJ, Holland EA, et al. Confirmation of chromosome 9p linkage to familial melanoma. Am J Hum Genet. 1993;53:936–942
  7. Gruis NA, Sandkuijl LA, Weber JL, et al. Linkage analysis in Dutch familial atypical multiple-mole melanoma (FAMMM) syndrome families (Effect of naevus count). Melanoma Res. 1993;3:271–277
  8. Goldstein AM, Dracopoli NC, Engelstein M, et al. Linkage of cutaneous malignant melanoma/dysplastic nevi to chromosome 9p, and evidence for genetic heterogeneity. Am J Hum Genet. 1994;54:489–496
  9. Hussussian CJ, Struewing JP, Goldstein AM, et al. Germline p16 mutations in familial melanoma. Nat Genet. 1994;8:15–21
  10. MacGeoch C, Bishop JA, Bataille V, et al. Genetic heterogeneity in familial malignant melanoma. Hum Mol Genet. 1994;3:2195–2200
  11. Holland EA, Beaton SC, Becker TM, et al. Analysis of the p16 gene, CDKN2, in 17 Australian melanoma kindreds. Oncogene. 1995;11:2289–2294
  12. Flores J, Pollock PM, Walker GJ, et al. Analysis of the CDK2NA, CDKN2B and CDK4 genes in 48 Australian melanoma kindreds. Oncogene. 1997;15:2999–3005
  13. Halaban R, Miglarese MR, Smicun Y, et al. Melanomas, from the cell cycle point of view. Int J Mol Med. 1998;1:419–425
  14. Isshiki K, Seng BA, Elder DE, et al. Chromosome 9 deletion in sporadic and familial melanomas in vivo. Oncogene. 1994;9:1649–1653
  15. Nobori T, Miura K, Wu DJ, et al. Deletions of the cyclin-dependent kinase-4 inhibitor gene in multiple human cancers. Nature. 1994;268:753–756
  16. Ohta M, Nagai H, Shimizu M, et al. Rarity of somatic and germline mutations of the cyclin-dependent kinase 4 inhibitor gene, CDK4I, in melanoma. Cancer Res. 1994;54:5269–5272
  17. Ohta M, Berd D, Shimizu M, et al. Deletion mapping of chromosome region 9p21-p22 surrounding the CDKN2 locus in melanoma. Int J Cancer. 1996;65:762–767
  18. Walker GJ, Palmer JM, Walters MK, et al. Genetic models of melanoma tumorigenesis based on allelic losses. Genes Chromosomes Cancer. 1995;12:134–141
  19. Luca M, Xie S, Gutman M, et al. Abnormalities in the CDKN2A (p16INK4/MTS-1) gene in human melanoma cells: relevance to tumor growth and metastasis. Oncogene. 1995;11:1399–1402
  20. Platz A, Hansson J, Mansson-Brahms E, et al. Screening of germline mutations in the CDKN2A genes in Swedish families with hereditary utaneous melanoma. J Natl Cancer Inst. 1997;89:697–702
  21. Hogg D, Brill H, Liu L, et al. Role of the cyclin-dependent kinase inhibitor CDKN2A in familial melanoma. J Cutan Med Surg. 1998;2:172–179
  22. Monzon J, Liu L, Brill H, et al. CDKN2A mutations in multiple primary melanomas. N Engl J Med. 1998;338:879–887
  23. Kovar H, Jug G, Ayre DNT, et al. Among genes involved in the RB dependent cell cycle regulatory cascade, the p16 tumor suppressor gene is frequently lost in the Ewing family of tumors. Oncogene. 1997;165:2225–2232
  24. Grana X, Reddy EP. Cell cycle control in mammalian cells: Role of cyclins, cyclin dependent kinases (CDK’s), growth suppressor genes and cyclin-dependent kinase inhibitors (CKI’s). Oncogene. 1995;11:211–219
  25. Harland M, Meloni R, Gruis N, et al. Germline mutations of the CDKN2 gene in UK melanoma families. Hum Mol Genet. 1997;6:2061–2067
  26. Hashemi J, Linder S, Platz A, et al. Melanoma development in relation to non-functional p16/INK4a protein and dysplastic nevus syndrome in Swedish melanoma kindreds. Melanoma Res. 1999;9:21–30
  27. Lee JY, Dong SM, Shin MS, et al. Genetic alterations of p16INK4a and p53 genes in sporadic dysplastic nevus. Biochem Biophys Res Commun. 1997;237:667–672
  28. Park WS, Vortmeyer AO, Pack S, et al. Allelic deletion at chromosome 9p21 (p16) and 17p13 (p53) in microdissected sporadic dysplastic nevus. Hum Pathol. 1998;29:127–130
  29. Whiteman DC, Milligan A, Welch J, et al. Germline CDKN2A mutations in childhood melanoma (letter). J Natl Cancer Inst. 1997;89:1460
  30. Robertson GP, Goldberg EK, Lugo TG, et al. Functional localization of a melanoma tumor suppressor gene to a small (< or = 2 Mb) region on 11q23. Oncogene. 1999;18:3173–3180
  31. Walker GJ, Nancarrow DJ, Walters MK, et al. Linkage analysis in familial melanoma kindreds to markers on chromosome 6p. Int J Cancer. 1994;59:771–775
  32. Goldstein AM, Goldin LR, Dracopoli NC, et al. Two-locus linkage analysis of cutaneous malignant melanoma/dysplastic nevi. Am J Hum Genet. 1996;58:1050–1056
  33. Platz A, Hansson J, Ringborg U. Screening of germline mutations in the CDK4, CDKN2C and TP53 genes in familial melanoma: A clinic-based population study. Int J Cancer. 1998;78:13–15
  34. Battistutta D, Palmer J, Walters M, et al. Incidence of familial melanoma and MLM2 gene. Lancet. 1994;344:1607–1608
  35. Soler-Carrillo J, Puig S, Palou J, et al. p16 protein expression as an important prognostic factor in primary cutaneous malignant melanoma. Am J Dermatopathol. 1998;20:603;(abstr)
  36. Fujimoto A, Morita R, Hatta N, et al. p16INK4a inactivation is not frequent in uncultured sporadic primary melanoma. Oncogene. 1999;18:2527–2532
  37. Hecht F, Hecht BK. Chromosome rearrangements in dysplastic nevus syndrome predisposing to malignant melanoma. Cancer Genet Cytogenet. 1998;35:73–78
  38. Puig S, Ruiz A, Lazaro C, et al. Chromosome 9p deletions in cutaneous malignant melanoma tumors: the minimal deleted region involves markers outside the p16 (CDNK2) gene. Am J Hum Genet. 1995;57:395–402
  39. Healy E, Rehman I, Angus B, et al. Loss of heterozygosity in sporadic primary melanoma. Genes Chromosomes Cancer. 1995;12:152–156
  40. Healy E, Belgaid CE, Takata M, et al. Allelotypes of primary cutaneous melanoma and benign melanocytic nevi. Cancer Res. 1996;56:589–593
  41. Dracopoli NC, Fountain JW. CDNK2 mutations in melanoma. Cancer Surv. 1995;26:115–132
  42. Morita R, Fujimoto A, Hatta N, et al. Comparison of genetic profiles between primary melanomas and their metastases reveals genetic alterations and clonal evolution during progression. J Invest Dermatol. 1998;111:919–924
  43. Gonzalez-Gomes P, Bello MJ, Alonso ME, et al. Promotor methylation status of multiple genes in brain metastases of solid tumors. Int J Mol Med. 2004;13:93–98
  44. Sviderskaya EV, Gray-Schopfer VC, Hill SP, et al. p16/cyclin-dependent kinase inhibitor 2A deficiency in human melanocyte senescence, apoptosis, and immortalization: Possible implications for melanoma progression. J Natl Cancer Inst. 2003;95:723–732
  45. Bandyopadhyay D, Medrano EE. Melanin accumulation accelerates melanocyte sensescence by a mechanism involving p16INK4a/CDK4/pRB and E2F1. Ann N Y Acad Sci. 2000;908:71–84
  46. Moan J, Dahlback A, Setlow RB. Epidemiological support for an hypothesis for melanoma induction indication of a role for UVA radiation. Photochem Photobiol. 1999;70:243–247
  47. Huot TJ, Rowe J, Harland M, et al. Biallelic mutations in p16(INK4a) confer resistance to Ras- and Ets-induced senescence in human diploid fibroblasts. Mol Cell Biol. 2002;22:8135–8143
  48. Cerroni L, Soyer P, Kerl H. bcl-2 protein expression in cutaneous malignant melanoma and benign melanocytic nevi. Am J Dermatopathol. 1995;17:7–11
  49. Morales-Ducret CRJ, van de Rijn M, Smoller BR. Bcl-2 expression in melanocytic nevi. Arch Dermatol. 1995;131:915–918
  50. Ramsey JA, From L, Kahn HJ. Bcl-2 protein expression in melanocytic neoplasms of the skin. Mod Pathol. 1995;8:150–154
  51. Saenz-Santamaria MC, Reed JA, McNutt NS, et al. Immunohistochemical expression of BCL-2 in melanomas and intradermal nevi. J Cutan Pathol. 1994;21:393–397
  52. Crowson AN, Magro CM, Kadin M, et al. Differential expression of bcl-2 oncogene in human basal cell carcinoma. Hum Pathol. 1996;27:355–359
  53. Crowson AN, Pilavdzic D, Stranc M, et al. Expression of p21WAF1/CIP1 in aggressive- versus non-aggressive-growth basal cell carcinoma: A comparative study. Lab Invest. 1999;79:56A;(abstr)
  54. Peris K, Keller G, Chimenti S, et al. Microsatellite instability and loss of heterozygosity in melanoma. J Invest Dermatol. 1995;105:625–628
  55. Bastian BC, Olshen AB, LeBoit PE, et al. Classifying melanocytic tumors based on DNA copy number changes. Am J Pathol. 2003;163:1765–1770
  56. Eberle J, Fecker LF, Hossini AM, et al. CD95/Fas signaling in human melanoma cells: Conditional expression of CD95L/FasL overcomes the intrinsic apoptosis resistance of malignant melanoma and inhibits growth and progression of human melanoma xenotransplants. Oncogene. 2003;22:9131–9141
  57. Mouawad R, Antoine EC, Khayat D, et al. Effect of endogenous interleukin-6 on Fas (APO-1/CD95) receptor expression in advanced melanoma patients. Cytokines Cell Mol Ther. 2000;6:135–140
  58. Kamei T, Inui M, Nakamura S, et al. Interferon-gamma and anti-Fas antibody-induced apoptosis in human melanoma cell lines and its relationship to bcl-2 cleavage. Melanoma Res. 2003;13:153–159
  59. Aragane Y, Maeda A, Cui CY, et al. Inhibition of growth of melanoma cells by CD95 (Fas/APO-1) gene transfer in vivo. J Invest Dermatol. 2000;115:1008–1014
  60. Mouawad R, Khayat D, Soubrane C. Plasma Fas ligand, an inducer of apoptosis, and plasma soluble Fas, an inhibitor of apoptosis, in advanced melanoma. Melanoma Res. 2000;10:461–467
  61. Ekmekcioglu S, Okcu MF, Colome-Grimmer MI, et al. Differential increase of Fas ligand expression on metastatic and thin or thick primary melanoma cells compared with interleukin-10. Melanoma Res. 1999;9:261–272
  62. Soubrane C, Mouawad R, Antoine EC, et al. A comparative study of Fas and Fas-ligand expression during melanoma progression. Br J Dermatol. 2000;143:307–312
  63. Faraoni I, Graziani G, Turriziani M, et al. Suppression of telomerase activity as an indicator of drug-induced cytotoxicity against cancer cells: In vitro studies with fresh human tumor samples. Lab Invest. 1999;79:993–1005
  64. Jong HS, Park YI, Sim S, et al. Up-regulation of human telomerase catalytic subunit during gastric carcinogenesis. Cancer. 1999;86:559–565
  65. Kugoh H, Shigenami K, Funaki K, et al. Human chromosome 5 carries a putative telomerase repressor gene. Genes Chromosomes Cancer. 2003;36:37–47
  66. Novakovic S, Hocevar M, Zgajnar J, et al. Detection of telomerase RNA in the plasma of patients with breast cancer, malignant melanoma or thyroid cancer. Oncol Rep. 2004;11:245–252
  67. Slater M, Scolyer RA, Gidley-Baird A, et al. Increased expression of apoptoic markes in melanoma. Melanoma Res. 2003;13:137–145
  68. Rudolph P, Schubert C, Tamm S, et al. Telomerase activity in melanocytic lesions: A potential marker of tumor biology. Am J Pathol. 2000;156:1425–1432
  69. Becker B, Muthoff G, Farkas B, et al. Induction of Hsp90 protein expression in malignant melanomas and melanoma metastases. Exp Dermatol. 2004;13:27–32
  70. Smith CD, Blackburn EH. Uncapping and deregulation of telomeres lead to detrimental consequences in yeast. J Cell Biol. 1999;145:203–214
  71. Kerl H, Soyer HP, Cerroni L, et al. Ancient melanocytic nevus. Semin Diagn Pathol. 1998;15:210–215
  72. Yawata T, Kamino H, Kugoh H, et al. Identification of a </=600-kb region on human chromosome 1q42.3 inducing cellular senescence. Oncogene. 2003;22:281–290
  73. Verra NC, Jorritsma A, Weijer K, et al. Human telomerase reverse transcriptase-transduced human cytotoxic T-cells suppress the growth of human melanoma in immunodeficient mice. Cancer Res. 2004;64:2153–2161
  74. Curtin JA, Fridlyand J, Kagashita T, et al. Distinct sets of genetic alterations in melanoma. New Engl J Med. 2005;353:2104–2107
  75. Curtin JA, Busam K, Pinkel D, et al. Somatic activation of KIT in distinctive subtypes of melanoma. J Clin Oncol. 2006;24:4340–4346
  76. Easty DJ, Bennett DC. Protein tyrosine kinases in malignant melanoma. Melanoma Res. 2000;10:401–411
  77. McMahon G. VEGF signalling in tumor angiogenesis. Oncologist. 2000;5(suppl 1):3–10
  78. Urquhart JL, Meech SJ, Marr DG, et al. Regulation of Fas-mediated apoptosis by N-ras in melanomas. J Invest Dermatol. 2002;119:556–561
  79. Ramon y Cajal S, Suster S, Halaban R, et al. Induction of different morphological features of malignant melanoma and pigmented lesions after transformation of murine melanocytes with bFGF-cDNA and H-ras, myc, neu and E1a oncogenes. Am J Pathol. 1991;138:349–358
  80. Otto FJ, Goldmann T, Biess B, et al. Prognostic classification of malignant melanoma by combining clinical, histological, and immunohistochemical parameters. Oncology. 1999;56:208–214
  81. Grover R, Chana J, Grobbelaar AO, et al. Measurement of c-myc oncogene expression provides an accurate prognostic marker for acral lentiginous melanoma. Br J Plast Surg. 1999;52:122–126
  82. Grover R, Pacifico MD, Wilson GD, et al. Use of oncogene expression as an independent prognostic marker for primary melanoma. Ann Plast Surg. 2003;50:183–187
  83. Hussein MR, Haemel AK, Wood GS. Apoptosis and melanoma: Molecular mechansisms. J Pathol. 2003;199:275–288
  84. Biroccio A, Amodei S, Antonelli A, et al. Inhibition of c-Myc oncoprotein limits the growth of human melanoma cells by inducing cellular crisis. J Biol Chem. 2003;278:35693–35701
  85. Pastorino F, Brignole C, Marimpietri D, et al. Targeted liposomal c-myc antisense oligodeoxynucleotides induce apoptosis and inhibit tumor growth and metastases in human melanoma models. Clin Cancer Res. 2003;9:4594–4605
  86. Peltenburg LT, de Bruin EC, Meersma D, et al. C-Myc is able to sensitize human melanoma cells to diverse apoptotic triggers. Melanoma Res. 2004;14:3–12
  87. Utikal J, Leiter U, Udart M, et al. Expression of c-myc and bcl-2 in primary and advanced cutaneous melanoma. Cancer Invest. 2002;20:914–921
  88. Seykora JT, Jih D, Elenitsas R, et al. Gene expression profiling of melanocytic tumors. Am J Dermatopathol. 2003;25:6–11
  89. Kallioniemi A, Kallioniemi OP, Sudar D, et al. Comparative genomic hybridization for molecular cytogenetic analysis of solid tumors. Science. 1992;258:818–821
  90. Pinkel D, Segraves R, Sudar D, et al. High resolution analysis of DNA copy number variation using comparative genomic hybridization to microarrays. Nat Genet. 1998;20:207–211
  91. Snijders AM, Nowak N, Segraves R, et al. Assembly of microarrays for genome-wide measurement of DNA copy number. Nat Genet. 2001;29:263–264
  92. Albertson DG, Ylstra B, Segraves R, et al. Quantitative mapping of amplicon structure by array CGH identified CYP24 as a candidate oncogene. Nat Genet. 2000;25:144–146
  93. Ishkanian AS, Malloff CA, Watson SK, et al. A tiling resolution DNA microarray with complete coverage of the human genome. Nat Genet. 2004;36:299–303
  94. Bastian BC, LeBoit PE, Hamm H, et al. Chromosomal gains and losses in primary cutaneous melanomas detected by comparative genomic hybridization. Cancer Res. 1998;58:2170–2175
  95. Bastian BC, Kashani-Sabet M, Hamm H, et al. Gene amplifications characterize acral melanomas and permit the detection of occult tumor cells in the surrounding skin. Cancer Res. 2000;60:1968–1973
  96. Sauter ER, Yeo UC, von Stemm A, et al. Cyclin D1 is a candidate oncogene in cutaneous melanoma. Cancer Res. 2002;62:3200–3206
  97. Bastian BC, Wesselmann U, Pinkel D, et al. Molecular cytogenetic analysis of Spitz nevi shows clear differences to melanoma. J Invest Dermatol. 1999;113:1065–1069
  98. Winokur TS, Palazzo JP, Johnson WC, et al. Evaluation of DNA ploidy in dysplastic and Spitz nevi by flow cytometry. J Cutan Pathol. 1990;17:342–347
  99. Harvell JD, Bastian BC, LeBoit PE. Persistent (recurrent) Spitz nevi: A histopathologic, immunohistochemical, and molecular pathologic study of 22 cases. Am J Surg Pathol. 2002;26:654–661
  100. Maldonado JL, Timmerman L, Fridlyand J, et al. Mechanisms of cell-cycle arrest in Spitz nevi with constitutive activation of the MAP-kinase pathway. Am J Pathol. 2004;164:1783–1787
  101. Murphy DA, Makonnen S, Lassoued W, et al. Inhibition of tumor endothelial ERK activation, angiogenesis, and tumor growth by sorafenib (BAY 43-9006). Am J Pathol. 2006;169:1875–1885
  102. Gollob JA, Wilhelm S, Carter C, et al. Role of Raf kinase in cancer: Therapeutic potential of targeting the Raf/MEK/ERK signal transduction pathway. Semin Oncol. 2006;33:392–406
  103. Ramsay JA, From L, Iscoe NA, et al. MIB-1 proliferative activity is a significant prognostic factor in primary thick cutaneous melanomas. J Invest Dermatol. 1995;105:22–26
  104. Sparrow LE, English DR, Taran JM, et al. Prognostic significance of MIB-1 proliferative activity in thin melanomas and immunohistochemical analysis of MIB-1 proliferative activity in melanocytic tumors. Am J Dermatopathol. 1998;20:12–16
  105. Crowson AN, Magro CM, Mihm MC. The Melanocytic Proliferations: A Comprehensive Textbook of Pigmented Lesions. New York, NY: Wiley; 2001;
  106. Penneys N, Seigfried E, Nahass G, et al. Expression of proliferating cell nuclear antigen in Spitz nevus. J Am Acad Dermatol. 1995;32:964–967
  107. Vecchiato A, Rossi CR, Montesco MC, et al. Proliferating cell nuclear antigen (PCNA) and recurrence in patients with cutaneous melanoma. Melanoma Res. 1994;4:207–211
  108. Karlsson M, Boeryd B, Carstensen J, et al. Correlation of Ki-67 and PCNA to DNA ploidy, S-phase fraction and survival in uveal melanoma. Eur J Cancer. 1996;32A:357–362
  109. Niezabitowski A, Czajecki K, Rys J, et al. Prognostic evaluation of cutaneous malignant melanoma: A clinicopathological and immunohistochemical study. J Surg Oncol. 1999;70:150–160
  110. Goldmann T, Ribbert D, Suter L, et al. Tumor characteristics involved in the metastatic behaviour as an improvement in primary cutaneous melanoma prognostics. J Exp Clin Cancer Res. 1998;17:483–489
  111. Reddy VB, Gattuso P, Aranha G, et al. Cell proliferation markers in predicting metastases in malignant melanoma. J Cutan Pathol. 1995;22:248–251
  112. Karjalainen JM, Eskelinen MJ, Nordling S, et al. Mitotic rate and S-phase fraction as prognostic factors in stage I cutaneous malignant melanoma. Br J Cancer. 1998;77:1917–1925
  113. Crowson AN, Magro CM, Mihm MC. Prognosticators of melanoma and the sentinel lymph node. Mod Pathol. 2006;19:S71–S87
  114. Balch CM, Buzaid AC, Atkins MB, et al. A new American Joint Committee on Cancer staging system for cutaneous melanoma. Cancer. 2000;88:1484–1491
  115. Cochran AJ. Prediction of outcome for patients with cutaneous melanoma. Pigment Cell Res. 1997;10:162–167
  116. Hsu MY, Meier FE, Nesbit M, et al. E-cadherin expression in melanoma cells restores keratinocyte-mediated growth control and down-regulates expression of invasion-associated adhesion receptors. Am J Pathol. 2000;156:1515–1525
  117. Shih IM, Herlyn M. Role of growth factors and their receptors in the development and progression of melanoma. J Invest Dermatol. 1993;100(suppl):196S–203S
  118. Kato J, Wanebo H, Calabresi P, et al. Basic fibroblast growth factor production and growth factor receptors as potential targets for melanoma therapy. Melanoma Res. 1992;2:13–23
  119. Sparrow LE, Heenan PJ. Differential expression of epidermal growth factor receptor in melanocytic tumours demonstrated by immunohistochemistry and mRNA in situ hybridization. Australas J Dermatol. 1999;40:19–24
  120. Moretti S, Pinzi C, Spallanzani A, et al. Immunohistochemical evidence of cytokine networks during progression of human melanocytic lesions. Int J Cancer. 1999;84:160–168
  121. Rodeck U, Nishiyama T, Mauviel A. Independent regulation of growth and SMAD-mediated transcription by transforming growth factor beta in human melanoma cells. Cancer Res. 1999;59:547–550
  122. Xie S, Price JE, Luca M, et al. Dominant-negative CREB inhibits tumor growth and metastasis of human melanoma cells. Oncogene. 1997;15:2069–2075
  123. Reed JA, McNutt NS, Prieto VG, et al. Expression of transforming growth factor-beta 2 in malignant melanoma correlates with depth of tumor invasion (Implications for tumor progression). Am J Pathol. 1994;145:97–104
  124. Faasen AE, Mooradian DL, Tranquillo RT, et al. Cell surface CD44-related chondroitin sulfate proteoglycan is required for transforming growth factor-stimulated mouse melanoma cell motility and invasive behaviour on type I collagen. J Cell Sci. 1993;106:501–511
  125. Van Belle PA, Elenitsas R, Satyamoorthy K, et al. Progression-related expression of β3 integrin in melanomas and nevi. Hum Pathol. 1999;33:562–567
  126. Hieken TJ, Ronan SG, Farolan M, et al. Molecular prognostic markers in intermediate-thickness cutaneous malignant melanoma. Cancer. 1999;85:375–382
  127. Hieken TJ, Farolan M, Ronan SG, et al. Beta3 integrin expression in melanoma predicts subsequent metastasis. J Surg Res. 1996;63:169–173
  128. Hieken TJ, Ronan SG, Farolan M, et al. Beta 1 integrin expression: A marker of lymphatic metastases in cutaneous malignant melanoma. Anticancer Res. 1996;16:2321–2324
  129. Moretti S, Pinzi C, Berti E, et al. In situ expression of transforming growth factor beta is associated with melanoma progression and correlates with Ki67, HLA-DR and beta 3 integrin expression. Melanoma Res. 1997;7:313–321
  130. Gouon V, Tucker GC, Kraus-Berthier L, et al. Up-regulated expression of the beta3 integrin and the 92kDa gelatinase in human HT-144 melanoma cell tumors grown in nude mice. Int J Cancer. 1996;68:650–662
  131. Peticlerc E, Boutaud A, Presayko A, et al. New functions for non-collagenous domains of human collagen type IV (Novel integrin ligands inhibiting angiogenesis and tumor growth in vivo). J Biol Chem. 2000;275:8051–8061
  132. Shahan TA, Fawzi A, Bellon G, et al. Regulation of tumor cell chemtoaxis by type IV collagen is mediated by a Ca(2+)-dependent mechanism requiring CD47 and the integrin alpha(v)beta(3). J Biol Chem. 2000;275:4796–4802
  133. Thorne RF, Marshall JF, Shafren DR, et al. The inetgrins alpha 3 beta 1 and alpha 6 beta 1 physically and functionally associate with CD36 in human melanoma cells. J Biol Chem. 2000;275:35264–35275
  134. Fidler IJ, Schackert G, Zhang RD, et al. The biology of melanoma brain metastasis. Cancer Metastasis Rev. 1999;18:387–400
  135. Hofmann UB, Westphal JR, van Kraats AA, et al. Expression of integrin alpha(v)beta(3) correlates with activation of membrane-type matrix metalloproteinase-1 (MT1-MMP) and matrix metalloproteinase-2 (MMP-2) in human melanoma cells in vitro and in vivo. Int J Cancer. 2000;87:12–19
  136. Kageshita T, Hamby CV, Hirai S, et al. Alpha(v)beta3 expression on blood vessels and melanoma cells in primary lesions: Differential association with tumor progression and clinical prognosis. Cancer Immunol Immunother. 2000;49:314–318
  137. Seftor RE, Seftor EA, Hendrix MJ. Molecular role(s) for integrins in human melanoma invasion. Cancer Metastasis Rev. 1999;18:359–375
  138. Henriet P, Zhong ZD, Brooks PC, et al. Contact with fibrillar collagen inhibits melanoma cell proliferation by up-regulating p27KIP1. Proc Natl Acad Sci U S A. 2000;97:10026–10031
  139. Beliveau A, Berube M, Rousseau A, et al. Expression of integrin alpha5beta1 and MMPs associated with epithelioid cytomorphology and malignancy of uveal melanoma. Invest Ophthalmol Vis Sci. 2000;41:2363–2372
  140. Vihinen P, Nikkola J, Vlaykova T, et al. Prognostic value of beta1 integrin expression in metastatic melanoma. Melanoma Res. 2000;10:243–251
  141. Birch M, Mitchell S, Hart IR. Isolation and characterization of human melanoma cell variants expressing high and low levels of CD44. Cancer Res. 1991;51:6660–6667
  142. Leigh CJ, Palechek PL, Knutson JR, et al. CD44 expression in benign and malignant nevomelanocytic lesions. Hum Pathol. 1996;27:1288–1294
  143. Schaider H, Soyer HP, Heider KH, et al. CD44 and variants in melanocytic skin neoplasms. J Cutan Pathol. 1998;25:199–203
  144. Ichikawa T, Matsumoto J, Kaneko M, et al. Moesin and CD44 expression in cutaneous melanocytic tumours. Br J Dermatol. 1998;138:763–768
  145. Massi D, Franchi A, Borgogni L, et al. Osteonectin expression correlates with clinical outcome in thin cutaneous malignant melanomas. Hum Pathol. 1999;30:339–344
  146. Kuske MD, Johnson JP. Assignment of the human melanoma cell adhesion molecule gene (MCAM) to chromosome 11 band q23.3 by radiation hybrid mapping. Cytogenet Cell Genet. 1999;87:258
  147. Shih IM, Speicher D, Hsu MY, et al. Melanoma cell-cell interactions are mediated through heterophile Mel-CAM/ligand interaction. Cancer Res. 1997;57:3835–3840
  148. Mintz-Weber CS, Johnson JP. Identification of the elements regulating the expression of the cell adhesion molecule MCAM/MUC18. J Biol Chem. 2000;275:34672–34680
  149. Xie S, Luca M, Huang S, et al. Expression of MCAM/MUC 18 by human melanoma cells leads to increased tumor growth and metastasis. Cancer Res. 1997;57:2295–2303
  150. Shih IM. The role of CD146 (Mel-CAM) in biology and pathology. J Pathol. 1999;189:4–11
  151. Jean D, Bar-Eli M. Regulation of tumor growth and metastasis of human melanoma by the CREB transcription factor family. Mol Cell Biochem. 2000;212:19–28
  152. Jean D, Harbison M, McConkey DJ, et al. CREB and its associated proteins act as survival factors for human melanoma cells. J Biol Chem. 1998;273:24884–24890
  153. Ronai Z, Yang YM, Fuchs SY, et al. ATF2 confers radiation resistance to human melanoma cells. Oncogene. 1998;16:523–531
  154. Tada S, Hatoko M, Tanaka A, et al. Expression of desmoglein I and plakoglobin in skin carcinomas. J Cutan Pathol. 2000;27:24–29
  155. Riccioni L, Di Tommaso L, Collina G. Actin-rich desmoplastic malignant melanoma. Am J Dermatopathol. 1999;21:537–541
  156. Cunningham CC. Actin-binding protein requirement for cortical stability and efficient locomotion. Science. 1992;255:325–327
  157. Puches R, Smolle J, Rieger E, et al. Expression of cytoskeletal components in melanocytic skin lesions (An immunohistochemical study). Am J Dermatopathol. 1991;13:137–144
  158. Tsukamoto H, Mishima Y, Hayashibe K, et al. Alpha-smooth muscle actin expression in tumor and stromal cells of benign and malignant human pigment tumors. J Invest Dermatol. 1992;98:116–120
  159. Shimokawa-Kuroki R, Sadano H, Taniguchi S. A variant actin (beta m) reduces metastases of mouse B16 melanoma. Int J Cancer. 1994;56:689–697
  160. Chu YW, Sefor EA, Romer LH, et al. Experimental coexpression of vimentin and keratin intermediate filaments in human melanoma cells augments motility. Am J Pathol. 1996;148:63–69
  161. Duncan LM, Bouffard D, Howard C, et al. In situ distribution of integrin alpha 2 beta 1 and alpha-actinin in melanocytic proliferations. Mod Pathol. 1996;9:938–943
  162. Bouffard D, Duncan LM, Howard CA, et al. Actin-binding protein expression in benign and malignant melanocytic proliferations. Hum Pathol. 1994;25:709–714
  163. Byers HR, Etoh T, Vink J, et al. Actin organization and cell migration of melanoma cells relate to differential expression of integrins and actin-associated proteins. J Dermatol. 1992;19:847–852
  164. Helige C, Zellnig G, Hofman-Wellenhof R, et al. Interrelation of motility, cytoskeletal organization and gap junctional communication with invasiveness of melanocytic cells in vitro. Invasion Metastasis. 1997;17:26–41
  165. Dewhurst LO, Rennie IG, MacNeil S. Positive attachment between cytoskeletal changes, melanoma cell attachment and invasion in vitro. Melanoma Res. 1998;8:303–311
  166. Voura EB, Sandig M, Kalnins VI, et al. Cell shape changes and cytoskelton reorganization during transmigration of human melanoma cells. Cell Tissue Res. 1998;293:375–387
  167. Leonardi A, Ellinger-Ziegelbauer H, Franzoso G, et al. Physical and functional interaction of filamin (actin-binding protein 280) and tumor necrosis factor receptor-associated factor 2. J Biol Chem. 2000;2745:271–278
  168. Vaisanen A, Kallioinen M, Taskinen PJ, et al. Prognostic value of MMP-2 immunoreactive protein (72kD type IV collagenase) in primary skin melanoma. J Pathol. 1998;186:51–58
  169. Ntayi C, Hornebeck W, Bernard P. [Involvement of matrix metalloproteinases (MMPs) in cutaneous melanoma progression]. Pathol Biol (Paris). 2004;52:154–159
  170. Airola K, Karonen T, Vaalamo M, et al. Expression of collagenases-1 and −3 and their inhibitors TIMP-1 and −3 correlates with the level of invasion in malignant melanomas. Br J Cancer. 1999;80:733–743
  171. Iida J, Wilhelmson KL, Price MA, et al. Membrane type-1 matrix metalloproteinase promotes human melanoma invasion and growth. J Invest Dermatol. 2004;122:167–176
  172. Eves P, Katerinaki F, Simpson C, et al. Melanoma invasion in reconstructed human skin is influenced by skin cells—Investigation of the role of proteolytic enzymes. Clin Exp Metastasis. 2003;20:685–700
  173. Ntayi C, Hornebeck W, Bernard P. Influence of cultured dermal fibroblasts on human melanoma cell proliferation, matrix metalloproteinase-2 (MMP-2) expression and invasion in vitro. Arch Dermatol Res. 2003;295:236–241
  174. Ramont L, Pasco S, Hornebeck W, et al. Transforming growth factor-beta 1 inhibits tumor growth in a mouse model by down-regulating the plasminogen activation system. Exp Cell Res. 2003;291:1–10
  175. Podhajcer OL, Bover L, Bravo AI, et al. Expression of cathepsin D in primary and metastatic melanoma and dysplastic nevi. J Invest Dermatol. 1995;104:340–344
  176. Gontier E, Cario-Andre M, Vergnes P, et al. The ‘Abtropfung phenonmenon’ revisited: Dermal nevus cells from congenital nevi cannot activiate matrix metalloproteinase 2 (MMP-2). Pigment Cell Res. 2003;16:366–373
  177. Wylie S, MacDonald IC, Varghese HJ, et al. The matrix metalloproteinase inhibitor batimastat inhibits angiogenesis in liver metastases of B16F1 melanoma cells. Clin Exp Metastasis. 1999;17:111–117
  178. Henriet P, Blavier L, Declerck YA. Tissue inhibitors of metalloproteinase (TIMP) in invasion and proliferation. APMIS. 1999;107:111–119
  179. Baker AH, George SJ, Zaltsman AB, et al. Inhibition of invasion and induction of cell death of cancer cell lines by overexpression of TIMP-3. Br J Cancer. 1999;79:1347–1355
  180. Ahonene M, Poukkula M, Baker AH, et al. Tissue inhibitor of metalloproteinase-3 induces apoptosis in melanoma cells by stabilization of death receptors. Oncogene. 2003;22:2121–2134
  181. Naylor MF, Crowson N, Kuwahara R, et al. Treatment of lentigo maligna with topical imiquimod. Br J Dermatol. 2003;149(suppl 66):66–69
  182. Hesling C, D’Incan M, Mansard S, et al. In vivo and in situ modulation of the expression of genes involved in metastasis and angiogenesis in a patient treated with topical imiquimod for melanoma skin metastases. Br J Dermatol. 2004;150:761–767
  183. Iwamoto S, Odland PB, Piepkorn M, et al. Evidence that the p75 neurotrophin receptor mediates perineural spread of desmoplastic melanoma. J Am Acad Dermatol. 1996;35:725–731
  184. Marchetti D, Aucoin R, Blust J, et al. p75 neurotrophin receptor functions as a survival receptor in brain-metastastic melanoma cells. J Cell Biochem. 2004;91:206–215
  185. Reed JA, McNutt NS, Albino AP. Differential expression of basic fibroblastic growth factor (bFGF) in melanocytic lesions demonstrated by in situ hybridization (Implications for tumor progression). Am J Pathol. 1994;144:329–336
  186. Nesbit M, Nesbit HK, Bennett J, et al. Basic fibroblast growth factor induces a transformed phenotype in normal human melanocytes. Oncogene. 1999;18:6469–6476
  187. Meir F, Nesbit M, Hsu MY, et al. Human melanoma progression in skin reconstructs: biological significance of bFGF. Am J Pathol. 2000;156:193–200
  188. Auslender S, Barzilai A, Goldberg I, et al. Lentigo maligna and superficial spreading melanoma are different in their in situ phase: An immunohistochemical study. Hum Pathol. 2002;33:1001–1005
  189. Singh RK, Gutman M, Radinsky R. Heterogeneity of cytokine and growth factor gene expression in human melanoma cells with metastatic potentials. J Interferon Cytokine Res. 1995;15:81–87
  190. Danielsen T, Fofstad EK. VEGF, bFGF and EGF in the angiogenesis of human melanoma xenografts. Int J Cancer. 1998;76:836–841
  191. Ribatti D, Vacca A, Ria R, et al. Neovascularization, expression of fibroblast growth factor-2 and mast cells with tryptase activity increase simultaneously with pathological expression in human malignant melanoma. Eur J Cancer. 2003;39:666–674
  192. Reed JA, McNutt NS, Bogdany JK, et al. Expression of the mast cell growth factor interleukin-3 in melanocytic lesions correlates with an increased number of mast cells in the perilesional stroma: implications for melanoma progression. J Cutan Pathol. 1996;23:495–505
  193. Al-Alousi S, Carlson JA, Blessing K, et al. Expression of basic fibroblast growth factor in desmoplastic melanoma. J Cutan Pathol. 1996;23:118–125
  194. Fearns C, Dowdle EB. The desmoplastic response: Induction of collagen synthesis by melanoma cells in vitro. Int J Cancer. 1992;50:621–627
  195. Lugassy C, Christensen L, Le Charpentier M, et al. Ultrastructural observations concerning laminin in B16 melanoma (Is an amorphous form of laminin promoting a non hematogenous migration of tumor cells?). J Submicrosc Cytol Pathol. 1998;30:137–144
  196. Lugassy C, Christensen L, Le Charpentier M, et al. Angio-tumoral laminin in murine tumors derived from human melanoma cell lines (Immunohistochemical and ultrastructural observations). J Submicrosc Cytol Pathol. 1998;30:231–237
  197. Lugassy C, Dickersin GR, Christensen L, et al. Ultrastructural and immunohistochemical studies of the periendothelial matrix in human melanoma: Evidence for an amorphous matrix containing laminin. J Cutan Pathol. 1999;26:78–83
  198. Lugassy C, Shahsafaei A, Bonitz P, et al. Tumor microvessels in melanoma express the beta-2 chain of laminin (Implications for melanoma metastases). J Cutan Pathol. 1999;26:222–226

PII: S0093-7754(07)00177-7

doi: 10.1053/j.seminoncol.2007.09.007

Seminars in Oncology
Volume 34, Issue 6 , Pages 476-490 , December 2007

Article Tools

* Image Usage & Resolution